Abstract
Abstract 4402
Dysfunction in cellular and humoral immunity entails an increased risk of B-cell chronic lymphocytic leukemia (B-CLL). It has been suggested that innate immunity, especially natural killers cells play key role in antitumor cytotoxicity regulated by interaction between killer immunoglobulin-like receptors (KIRs) on NK cells and some T-cell subpopulations and their HLA-class I ligands on target cells. KIRs receptors have been divided into two functional groups: with long cytoplasmic tails (DL) - inhibitory and with short cytoplasmic tails (DS) - activating. Two broad haplotypes of KIR genes have been defined: the A haplotype characterized by presence of single activating KIR gene (2DS4) and the B haloptype characterized by two or more activating KIR genes (2DS1, 2DS2, 2DS3, 2DS5 and 3DS1).The 2DL2, 2DL3 and 2DS2 KIRs bind to HLA-C1 allotype (Asp80), while 2DL1 and 2DS1 KIRs bind to HLA-C2 allotype (Lys80). Due to lack of representative data in literature the study was undertaken to determine the association between polymorphism of KIR genes and HLA-C allotypes and susceptibility to B-CLL.
The following KIR genes were typed: 2DL1, 2DL2, 2DL3, 3DL1, 2DS1, 2DS2, 2DS3, 2DS4fl, 2DS4del, 2DS5, 3DS1, in 200 B-CLL patients and 199 healthy individuals using PCR-SSP method. The HLA-C1 and HLA-C2 were determined using Olerup SSP typing kit in 187 B-CLL patients and 104 controls.
Individual KIR gene content was similar in B-CLL cases and healthy controls although patients with KIR2DS3 gene were more common among cases compared to controls (36% vs. 27%, p=0.06) (Table1). The frequency of AA haplotype did not differ between studied groups (29% vs. 28%). Moreover no differences were found between incidence of HLA-C allotypes (HLA-C1: 74.3% vs. 76.0%, HLA-C2: 67.4% vs.70.2%), genotypes (C1/C1: 32.6% vs 29.8%, C1/C2: 41.7% vs 46,2% and C2/C2: 25.7% vs 24.1) and KIR genes in combination with genes for their HLA-C ligands in B-CLL patients and controls (Table 2).
. | 2DL1 . | 2DL2 . | 2DL3 . | 2DS1 . | 2DS2 . | 2DS3 . | 2DS4del . | 2DS4fl . | 2DS5 . | 3DL1 . | 3DS1 . |
---|---|---|---|---|---|---|---|---|---|---|---|
B-CLL (n=200) | 195 | 106 | 176 | 75 | 108 | 54 | 166 | 56 | 53 | 186 | 70 |
[%] | 97.5 | 53.0 | 88.0 | 37.5 | 54.0 | 27.0 | 83.0 | 28.0 | 26.5 | 93.0 | 35.0 |
Controls (n=199) | 197 | 106 | 180 | 81 | 111 | 71 | 162 | 58 | 61 | 181 | 78 |
[%] | 99.0 | 53.3 | 90.5 | 40.7 | 55.8 | 35.7 | 81.4 | 29.1 | 30.7 | 91.0 | 39.2 |
. | 2DL1 . | 2DL2 . | 2DL3 . | 2DS1 . | 2DS2 . | 2DS3 . | 2DS4del . | 2DS4fl . | 2DS5 . | 3DL1 . | 3DS1 . |
---|---|---|---|---|---|---|---|---|---|---|---|
B-CLL (n=200) | 195 | 106 | 176 | 75 | 108 | 54 | 166 | 56 | 53 | 186 | 70 |
[%] | 97.5 | 53.0 | 88.0 | 37.5 | 54.0 | 27.0 | 83.0 | 28.0 | 26.5 | 93.0 | 35.0 |
Controls (n=199) | 197 | 106 | 180 | 81 | 111 | 71 | 162 | 58 | 61 | 181 | 78 |
[%] | 99.0 | 53.3 | 90.5 | 40.7 | 55.8 | 35.7 | 81.4 | 29.1 | 30.7 | 91.0 | 39.2 |
. | B-CLL (n = 187) . | Controls (n = 104) . | ||
---|---|---|---|---|
N . | % . | N . | % . | |
2DL1+/C2+ | 122 | 65.24 | 73 | 70.19 |
2DL2/3+/C1+ | 139 | 74.33 | 79 | 75.96 |
2DS1+/C2+ | 49 | 26.20 | 24 | 23.08 |
2DS2+/C1+ | 71 | 37.97 | 40 | 38.46 |
2DL1+/C2- | 60 | 32.08 | 30 | 28.80 |
2DL2/3+/C1- | 48 | 25.69 | 25 | 24.04 |
2DS1+/C2- | 22 | 11.76 | 18 | 17.31 |
2DS2+/C1- | 19 | 10.37 | 11 | 10.58 |
. | B-CLL (n = 187) . | Controls (n = 104) . | ||
---|---|---|---|---|
N . | % . | N . | % . | |
2DL1+/C2+ | 122 | 65.24 | 73 | 70.19 |
2DL2/3+/C1+ | 139 | 74.33 | 79 | 75.96 |
2DS1+/C2+ | 49 | 26.20 | 24 | 23.08 |
2DS2+/C1+ | 71 | 37.97 | 40 | 38.46 |
2DL1+/C2- | 60 | 32.08 | 30 | 28.80 |
2DL2/3+/C1- | 48 | 25.69 | 25 | 24.04 |
2DS1+/C2- | 22 | 11.76 | 18 | 17.31 |
2DS2+/C1- | 19 | 10.37 | 11 | 10.58 |
The data obtain in this study imply that there may be not direct association between KIR and HLA-C gene content in the genome and the presence of B-CLL.
No relevant conflicts of interest to declare.
Author notes
Asterisk with author names denotes non-ASH members.